The earnings call highlighted significant revenue growth, positive clinical trial results for ifetroban, successful international expansion of Vibativ, and new strategic partnerships. No major challenges or negative trends were reported, suggesting a strong positive outlook for Cumberland Pharmaceuticals.

Company Guidance

During the Cumberland Pharmaceuticals second quarter 2025 financial report call, several key metrics and developments were highlighted. The company reported a 10% increase in quarterly revenues, reaching $10.8 million, compared to the same period last year. Year-to-date revenues for the first half of 2025 totaled $22.6 million, marking a 23% increase from the prior year. Adjusted earnings for the second quarter were reported at $0.4 million, with a year-to-date figure of $2.8 million or $0.18 per share. The company's portfolio of FDA-approved brands contributed to these results, including Vibativ, which saw regulatory approval in China and a new partnership in the Middle East. The company's balance sheet at the end of the quarter showed $68 million in total assets, $16 million in cash and cash equivalents, $40 million in liabilities, and $28 million in shareholders' equity. Cumberland's pipeline developments were also discussed, particularly the positive Phase II study results of ifetroban for Duchenne muscular dystrophy, with plans to meet the FDA to discuss further development.

Strong Revenue Growth

Cumberland Pharmaceuticals reported a 10% increase in revenue for the second quarter of 2025, totaling $10.8 million. Year-to-date revenues for the first 6 months reached $22.6 million, marking a 23% increase over the prior year period.

Positive Clinical Developments for Ifetroban

Ifetroban showed a 5.4% improvement in cardiac functions for patients with Duchenne muscular dystrophy (DMD) and reduced cardiac damage biomarkers, positioning it as a potential treatment for DMD cardiomyopathy.

International Expansion of Vibativ

Vibativ received approval from Chinese regulatory authorities and is preparing for launch in China and the Middle East through a partnership with Tabuk Pharmaceuticals.

New Partnerships and Product Launches

Cumberland announced a new partnership with Qureight for deep learning image analytics to enhance clinical trial outcomes and a new distribution partnership with Vizient, providing access to Vibativ's 4-vial configuration.

Cumberland Pharmaceuticals (CPIX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CPIX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	- / -	-0.11	―	―	―
Aug 05, 2025	2025 (Q2)	- / -0.05	-0.077	35.06% (+0.03)	―
May 06, 2025	2025 (Q1)	- / 0.08	-0.138	159.42% (+0.22)	―
Mar 04, 2025	2024 (Q4)	- / -0.14	-0.444	69.37% (+0.31)	―
Nov 07, 2024	2024 (Q3)	- / -0.11	-0.074	-48.65% (-0.04)	―
Aug 06, 2024	2024 (Q2)	- / -0.08	0.06	-228.33% (-0.14)	―
May 07, 2024	2024 (Q1)	- / -0.14	0.013	-1161.54% (-0.15)	―
Mar 05, 2024	2023 (Q4)	- / -0.44	-0.17	-161.18% (-0.27)	―
Nov 07, 2023	2023 (Q3)	- / -0.07	-0.03	-146.67% (-0.04)	―
Aug 08, 2023	2023 (Q2)	- / 0.06	-0.09	166.67% (+0.15)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CPIX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$3.79	$3.21	-15.30%
May 06, 2025	$4.41	$4.42	+0.23%
Mar 04, 2025	$6.05	$6.77	+11.90%
Nov 07, 2024	$1.20	$1.19	-0.83%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cumberland Pharmaceuticals Inc (CPIX) report earnings?

Cumberland Pharmaceuticals Inc (CPIX) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).

What is Cumberland Pharmaceuticals Inc (CPIX) earnings time?

Cumberland Pharmaceuticals Inc (CPIX) earnings time is at Nov 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CPIX EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing